If the April 30 hearing on biomedical research before the U.S. Senate Appropriations Committee is any indication, the Trump administration could face a big challenge if it tries to cut more than 40% of the NIH’s budget in fiscal 2026 as proposed and slap a 15% cap on indirect costs.
Pulsed field ablation dominated discussions and scientific sessions at Heart Rhythm 2025 in San Diego with researchers and manufacturers touting new applications in persistent atrial fibrillation, atrial flutter and addressing specific challenges for existing systems.
The Trump administration’s tariff activities provoked another set of responses from both Medtech Europe and the Advanced Medical Technology Association.
The U.S. Centers for Medicare & Medicaid Services will hold an advisory meeting regarding devices for treatment of symptoms for Parkinson’s disease, but the agency indicated that it expects to see longer-term data for these treatments if manufacturers want Medicare coverage.
Health care technology company Wearoptimo Ltd. developed a next-generation microwearable sensor that accurately detects hydration levels, outperforming the needle-based gold standard.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adela, C the Signs, Calyxo, EDAP, Heartbeam, Inocras.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Akoya Biosciences, Allora, Astrazeneca, Evvy, Healthy.io, Heartcor, Icad, Labrador Health, Mainstay Medical, Microsoft, Neogenomics, Quanterix, Sophia Genetics, Ultima Genomic, Wellysis.
RSS
